marcella
bassetto
alberto
massarotti
antonio
coluccia
andrea
brancal
structur
biolog
emerg
last
thirti
year
power
tool
ration
drug
discoveri
crystal
structur
biolog
target
alon
complex
ligand
inhibitor
provid
essenti
insight
mechan
action
enzym
conform
chang
upon
ligand
bind
architectur
interact
bind
pocket
structurebas
method
crystallograph
fragment
screen
repres
nowaday
invalu
instrument
identif
new
biolog
activ
compound
context
threedimension
protein
structur
play
essenti
role
understand
activ
design
novel
antivir
agent
sever
differ
virus
review
evolut
resolut
viral
structur
analys
along
role
crystal
structur
discoveri
optimis
new
antivir
knowledg
threedimension
structur
protein
long
recognis
power
tool
acceler
drug
discoveri
provid
inform
target
shape
hydrophob
hydrophil
behaviour
macromolecul
interact
substrat
sinc
first
xray
diffract
structur
report
pepsin
method
emerg
invalu
sourc
detail
reliabl
inform
protein
structur
repres
signific
step
forward
comparison
previous
use
physic
chemic
method
idea
threedimension
structur
inform
could
use
defin
topographi
complementari
surfac
ligand
protein
target
rais
earli
scientist
start
use
inform
optimis
potenc
select
lead
compound
structur
detail
gather
target
structur
presenc
uniqu
ligand
provid
fundament
insight
geometr
fit
compound
bind
site
bind
activ
conform
molecular
electrostat
potenti
hydrophob
interact
nowaday
applic
structur
biolog
extend
assess
target
druggabl
identif
hit
virtual
screen
structurebas
virtual
screen
method
target
identif
structuresequ
homolog
recognit
last
three
decad
applic
structur
biolog
drug
discoveri
follow
classic
path
structurebas
becam
extrem
fashion
consequ
public
structur
first
import
drug
target
later
due
limit
number
protein
structur
avail
cost
time
requir
set
crystal
process
use
ration
approach
drop
favour
highthroughput
screen
method
combinatori
chemistri
success
stori
hiv
proteas
inhibitor
influenza
antivir
drug
relenza
led
renew
interest
target
structuredriven
drug
discoveri
furthermor
numer
advanc
scienc
technolog
promot
faster
less
expens
applic
structur
biolog
increas
speed
macromolecular
structur
determin
increas
resolut
new
crystal
structur
allow
smaller
amount
protein
fewer
crystal
requir
solv
structur
one
recent
applic
structur
biolog
crystallograph
fragment
screen
low
affin
target
characteris
chemic
fragment
made
unsuit
classic
high
throughput
screen
advanc
high
throughput
nmr
crystallographi
allow
use
structur
inform
proteinfrag
complex
provid
reliabl
proof
bind
pocket
hit
bind
mode
give
clear
indic
fragment
structur
optimis
potent
lead
compound
characterist
make
fragment
attract
start
point
iter
medicin
chemistri
optimis
sever
biolog
activ
compound
discov
structurebas
design
drug
market
confirm
crucial
role
play
structur
biolog
drug
develop
protein
structur
determin
becom
one
earliest
crucial
step
mani
drugdiscoveri
program
pharmaceut
compani
protein
data
bank
pdb
establish
curat
archiv
evolv
new
develop
structur
biolog
hold
pdb
continu
grow
usag
pdb
data
also
grow
million
download
ftp
websit
data
occur
pdb
site
compar
million
download
download
statist
overal
archiv
individu
entri
avail
wwpdb
websit
http
www
wwpdborgstatsdownload
first
atom
viral
structur
publish
less
year
ago
viral
relat
structur
avail
pdb
differ
viru
contain
virus
figur
b
viral
structur
pdb
around
determin
use
xray
crystallographi
figur
sinc
establish
archiv
number
structur
deposit
grown
steadili
averag
resolut
xray
structur
remain
constant
figur
howev
larg
volum
data
avail
substanti
number
structur
determin
high
resolut
includ
least
one
viral
structur
time
larg
macromolecular
machin
studi
use
xray
method
mani
exampl
low
resolut
structur
year
number
viral
pdb
entri
increas
increasingli
faster
rate
figur
analysi
taxonomi
pdb
show
studi
virus
respect
human
immunodefici
viru
enterobacteria
phage
influenza
viru
hepat
c
viru
hcv
human
herpesviru
sarscov
dengu
viru
norwalk
viru
vaccinia
viru
enteroviru
c
enteroviru
influenza
b
viru
murin
leukemia
viru
mlv
rsvsra
simian
foami
viru
foamv
figur
like
due
import
role
virus
play
biomed
research
top
viru
sequenc
cluster
analysi
tabl
preform
use
sequenc
ident
cutoff
cluster
expect
obtain
number
bigger
number
protein
viral
proteom
biomed
research
virus
involv
structur
biolog
highlight
figur
gener
interest
scientist
compar
entri
virus
pdb
search
pubm
databas
use
viru
name
reveal
number
origin
research
paper
publish
per
viru
surprisingli
growth
rate
public
pubm
alway
correl
number
pdb
entri
number
ligandvir
pdb
entri
continu
increas
complex
ligand
includ
differ
market
drug
tabl
one
strike
exampl
success
applic
structur
biolog
antivir
drug
discoveri
repres
proteas
reversetranscriptas
structur
biolog
antivir
drug
discoveri
bassetto
et
al
virus
inhibitor
recognis
respons
acquir
immun
defici
syndrom
aid
earli
discoveri
first
select
proteas
inhibitor
still
one
popular
exampl
use
xray
crystallographi
develop
drug
clinic
use
hiv
proteas
valid
potenti
drug
target
first
xray
crystal
structur
enzym
began
appear
first
hiv
proteas
inhibitor
saquinavir
licens
six
year
later
follow
approv
ritonavir
four
month
later
three
fundament
step
led
saquinavir
discoveri
first
one
classif
hiv
proteas
member
aspart
proteas
famili
compris
also
pepsin
renin
homolog
renin
alreadi
target
design
antihypertens
agent
suggest
potenti
approach
develop
select
inhibitor
enzym
research
interest
reinforc
resolut
first
crystal
structur
hiv
along
proteas
structur
relat
rou
sarcoma
viru
final
use
inform
proteas
inhibit
transitionst
analogu
inhibitor
guid
seri
investig
minimum
size
requir
small
molecul
inhibit
enzym
extens
structureact
relationship
studi
xray
experi
direct
address
aspect
result
discoveri
saquinavir
key
step
life
cycl
revers
transcript
rt
therefor
rtdna
polymeris
immedi
consid
prime
drug
target
first
approv
antiaid
drug
nucleosid
analogu
azt
zidovudin
zdv
hiv
revers
transcriptas
rt
heterodim
consist
two
polypeptid
chain
figur
chain
contain
ntermin
polymeras
domain
ctermin
rnase
h
domain
subdomain
flexibl
rearrang
differ
conform
state
requir
carri
enzym
essenti
function
viral
replic
sequenc
complet
rt
clinic
isol
shown
mutat
remot
connect
subdomain
rnase
h
domain
enhanc
resist
nucleosid
nrti
nonnucleosid
nnrti
inhibitor
follow
indirect
mechan
well
understood
sinc
public
first
crystal
structur
hiv
reversetranscriptas
complex
nonnucleosid
inhibitor
nevirapin
resolut
structur
sever
conform
complex
differ
inhibitor
provid
extrem
power
tool
gain
essenti
insight
mechan
action
enzym
understand
import
flexibl
differ
conform
state
rationalis
occurr
resist
elucid
bind
nucleosid
nonnucleosid
inhibitor
design
optimis
new
chemic
agent
target
protein
among
sever
exampl
avail
structur
biolog
essenti
design
optimis
new
nonnucleosid
inhibitor
rt
resolut
crystal
structur
enzym
complex
rnase
inhibitor
dihydroxi
benzoyl
naphthyl
hydrazon
dhbnh
figur
led
discoveri
novel
site
protein
near
antiinfect
polymeras
activ
site
nnrti
bind
pocket
structurebas
modif
dhbnh
scaffold
result
identif
dual
inhibitor
polymeras
rnh
activ
rt
exemplifi
compound
figur
recent
follow
resolut
crystal
structur
rt
contain
nnrti
dna
polymeras
domain
ahydroxytropolon
manicol
rnase
h
activ
site
structur
manicol
ration
modifi
obtain
new
seri
ahydroxytropolon
show
antivir
activ
noncytotox
concentr
occupi
addit
site
surround
dna
polymeras
catalyt
centr
compound
figur
applic
xray
crystallograph
fragment
screen
methodolog
evalu
intrins
flexibl
rt
discoveri
new
alloster
site
seven
new
site
identifi
within
protein
three
site
name
knuckl
nnrti
adjac
incom
nucleotid
bind
site
proven
inhibitori
enzymat
assay
cocrystallis
fragment
figur
found
novel
scaffold
comparison
previous
report
rt
inhibitor
thu
provid
basi
develop
novel
lead
resolut
crystal
structur
rt
complex
potent
pyrimidinebas
nnrti
structurebas
modif
chemic
scaffold
direct
occup
entranc
channel
nnrti
bind
site
result
identif
much
solubl
analogu
figur
solubl
issu
associ
significantli
improv
studi
sever
report
structur
enzym
complex
efavirenz
nonnucleosid
inhibitor
inspect
ligand
structur
biolog
antivir
drug
discoveri
bassetto
et
al
tabl
divers
pdb
entri
viral
pdb
entri
analys
use
sequenc
ident
cutoff
identifi
cluster
geometri
requir
interact
enzym
reveal
structur
guid
design
new
seri
arylphosphoindol
potent
inhibitor
enzym
exemplifi
compound
figur
subsequ
ration
optimis
origin
lead
result
identif
nanomolar
inhibitor
doubl
mutant
mutat
clinic
relev
reach
phase
iib
clinic
trial
year
multipl
rt
crystal
structur
use
silico
screen
librari
two
million
compound
use
molecular
dock
method
take
account
differ
protein
conform
order
overcom
resist
one
hit
found
mm
potenc
wt
compound
figur
comput
analys
ration
modif
structur
led
discoveri
catechol
diether
antihiv
agent
retain
nanomolar
activ
mutant
structur
biolog
often
extrem
help
identif
optimis
novel
antivir
agent
also
case
hcv
particular
discoveri
novel
inhibitor
protein
polymeras
fragmentbas
screen
fragment
full
length
hcv
genotyp
enzym
led
discoveri
new
alloster
pocket
interfac
proteas
helicas
domain
structurebas
optimis
first
hit
found
bind
new
pocket
compound
figur
guid
identif
potent
inhibitor
figur
also
inhibit
viral
replic
ec
valu
nanomolar
rang
crystallograph
fragmentbas
screen
methodolog
proven
success
also
identif
nonnucleosid
inhibitor
hcv
polymeras
small
bromoaryl
fragment
found
bind
thumb
domain
protein
initi
bind
affin
millimolar
rang
seri
structurebas
optimis
cycl
fragment
scaffold
led
identif
famili
structur
high
affin
enzym
low
micromolar
activ
hcv
replicon
assay
compound
figur
recent
applic
similar
fragmentbas
approach
guid
identif
sulfonamid
fragment
figur
bind
polymeras
alloster
thumb
pocket
scaffold
small
fragment
start
point
differ
structurebas
modif
result
identif
phenoxyantranil
acid
sulfonamid
deriv
potent
inhibitor
hcv
polymeras
structurebas
optimis
attempt
scaffold
led
discoveri
deriv
slightli
potent
inhibit
enzym
show
much
potent
inhibit
viral
replic
cell
cultur
ec
nm
along
fragmentbas
screen
method
structurebas
design
optimis
techniqu
play
import
role
discoveri
novel
nonnucleosid
antiinfect
inhibitor
hcv
polymeras
one
first
studi
report
structur
nonnucleosid
inhibitor
hit
identifi
biochem
ht
assay
resolv
complex
enzym
reveal
bind
alloster
region
thumb
palm
domain
start
examin
crystal
structur
seri
ration
modif
hit
scaffold
direct
better
occup
alloster
pocket
result
discoveri
potent
inhibitor
figur
ic
nm
activ
viral
replic
cellular
system
low
micromolar
rang
recent
exampl
structurebas
lead
optimis
includ
identif
novel
quinazolinon
chemotyp
thumb
pocket
alloster
inhibitor
antiinfect
current
opinion
pharmacolog
chemic
structur
rt
inhibitor
discov
optimis
use
structurebas
method
compound
figur
ration
design
follow
inspect
enzym
crystal
structur
complex
previous
report
alloster
inhibitor
crystal
structur
newli
design
quinazolinon
complex
enzym
resolv
structurebas
optimis
attempt
aim
improv
key
interact
within
protein
bind
channel
carri
result
identif
deriv
show
improv
potenc
biochem
cellular
antivir
assay
figur
final
start
crystal
structur
nonnucleosid
inhibitor
complex
polymeras
synthet
effort
direct
toward
optimis
interact
differ
subpocket
enzym
result
identif
sever
new
analogu
potent
antivir
activ
vitro
genotyp
high
metabol
stabil
good
oral
bioavail
repres
figur
anoth
interest
case
applic
structur
biolog
identif
hcv
nonnucleosid
inhibitor
report
structur
compound
attract
hit
deriv
biochem
ht
assay
larg
compound
collect
sequenti
optimis
use
combin
xray
crystallographi
nmr
analys
molecular
model
studi
along
bindingsit
resist
mutant
experi
structur
biolog
antivir
drug
discoveri
bassetto
et
al
current
opinion
pharmacolog
chemic
structur
nonnucleosid
inhibitor
hcv
polymeras
discov
optimis
structurebas
method
photoaffin
label
studi
approach
result
identif
differ
seri
new
analogu
significantli
improv
potenc
enzymat
assay
cellular
antivir
assay
exemplifi
compound
figur
mention
mani
case
structur
biolog
key
identif
novel
improv
antivir
involv
mani
virus
structur
inform
becom
avail
last
decad
includ
exampl
antivir
drug
market
neuraminidas
inhibitor
zanamivir
influenza
b
anoth
exampl
success
applic
structurebas
approach
recent
report
identif
new
class
influenza
endonucleas
inhibitor
figur
engin
highresolut
crystal
form
pandem
influenza
polymeras
acid
protein
ntermin
endonucleas
domain
use
crystallograph
fragment
screen
fragment
lead
identif
hit
fragment
show
bind
affin
enzym
rang
mm
also
reveal
presenc
third
metal
ion
activ
site
cleft
previous
unknown
differ
cycl
ration
modif
hit
scaffold
perform
order
maximis
interact
activ
site
enzym
structurebas
optimis
approach
result
identif
compound
show
antivir
ec
mm
figur
structur
biolog
fundament
also
understand
mechan
action
import
conform
flexibl
dengu
viru
polymeras
structurebas
method
extrem
use
discoveri
nonnucleosid
inhibitor
enzym
xraybas
screen
novarti
fragment
collect
dengu
polymeras
result
identif
biphenyl
acet
acid
figur
bound
novel
pocket
palm
subdomain
protein
grow
optimis
first
hit
crystallographi
computeraid
structurebas
design
led
develop
antivir
agent
activ
four
dengu
serotyp
ec
valu
low
micromolar
rang
among
exampl
structurebas
method
particularli
use
discoveri
novel
chemic
agent
enteroviru
noroviru
analysi
crystal
structur
complet
viral
particl
complex
uncoat
inhibitor
exemplifi
deriv
figur
combin
silico
dockingbas
method
guid
design
improv
potent
inhibitor
virusinduc
cytophat
effect
cell
compound
inhibit
full
rang
subtyp
recent
analysi
crystal
structur
proteinas
complex
moder
inhibitor
subsequ
structurebas
modif
scaffold
guid
design
improv
inhibitor
enzymat
viru
cellbas
assay
final
structurebas
fragmentwis
design
new
inhibitor
enzym
led
discoveri
new
chemic
scaffold
potent
inhibitor
enzym
activ
virusinduc
cytopath
effect
cell
case
noroviru
iter
process
structureguid
design
optimis
dipeptidyl
inhibitor
viral
proteas
guid
discoveri
potent
deriv
display
vivo
efficaci
murin
model
noroviru
infect
studi
viral
target
differ
crystal
structur
complex
peptidyl
inhibitor
recent
use
design
novel
triazolebas
macrocycl
inhibitor
repres
compound
figur
also
inhibit
viral
replic
cell
ec
valu
low
micromolar
rang
final
structur
biolog
essenti
also
identif
novel
inhibitor
noroviru
rnadepend
rnapolymeras
dockingbas
silico
search
method
polymeras
structur
use
commerci
avail
compound
led
discoveri
suramin
analogu
ppnd
novel
inhibitor
noroviru
rdrp
activ
resolut
crystal
structur
ppnd
complex
enzym
also
indic
possibl
target
new
bind
subpocket
thumb
domain
enzym
design
new
noroviru
inhibitor
follow
increas
number
viral
target
structur
deposit
pdb
structur
biolog
becom
fundament
tool
antivir
research
provid
essenti
insight
mechan
action
viral
enzym
interact
substrat
antivir
agent
repres
sever
case
basi
ration
discoveri
optimis
new
antivir
exemplifi
strike
case
drug
market
saquinavir
zanamivir
use
combin
comput
techniqu
structurebas
structur
biolog
antivir
drug
discoveri
bassetto
et
al
method
often
among
earliest
import
step
drugdiscoveri
campaign
pharmaceut
compani
fundament
applic
discoveri
new
antivir
expect
increas
next
year
support
continu
evolut
associ
technolog
